Regenerative agents versus autogenous bone graft for alveolar cleft reconstruction: a systematic review and network meta-analysis

Article information

Arch Craniofac Surg. 2026;27(5):219-237
Publication date (electronic) : 2026 October 20
doi : https://doi.org/10.7181/acfs.2026.0106
1Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Hasanuddin University, Makassar, Indonesia
2Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Muhammadiyah University of Palangka Raya, Palangka Raya, Indonesia
3Hasanuddin University Dental Hospital, Makassar, Indonesia
4Dentistry Study Program, Faculty of Medicine, State University of Surabaya, Surabaya, Indonesia
5Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Lambung Mangkurat University, Banjarmasin, Indonesia
Correspondence: Andi Tajrin Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Hasanuddin University, Perintis Kemerdekaan Street No. 10, Tamalanrea, Makassar 90245, Indonesia E-mail: anditajrin@unhas.ac.id
Received 2026 July 7; Revised 2026 September 30; Accepted 2026 October 20.

Abstract

Background

Autogenous iliac crest bone graft is the standard for alveolar cleft reconstruction, but donor-site morbidity has prompted interest in regenerative agents. This review compared and ranked these agents against autogenous bone and one another.

Methods

Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for network meta-analyses, six databases were searched from January 2000 to June 2026 for controlled studies comparing a regenerative agent with autogenous bone graft. Risk of bias was assessed using version 2 of the Cochrane risk-of-bias tool for randomized trials and the ROBINS-I tool; certainty was assessed using Grading of Recommendations Assessment, Development and Evaluation. A frequentist random-effects network meta-analysis used autogenous bone as the reference and P-scores to rank treatments for new bone formation, bone density, graft volume, and graft success.

Results

Twenty-one studies (23 reports) were included. Platelet-rich fibrin (risk ratio [RR], 1.46; 95% confidence interval [CI], 1.07–2.01) and concentrated growth factor (RR, 1.21; 95% CI, 1.02–1.43) were superior to autograft for graft success; platelet-rich fibrin ranked first (P-score, 0.87) and exceeded recombinant human bone morphogenetic protein-2 (RR, 1.44; 95% CI, 1.04–1.99). In one trial, bone marrow aspirate concentrate increased graft volume (standardized mean difference, 2.36; 95% CI, 1.51–3.21). No agent increased new bone formation or bone density. Certainty was moderate for one comparison, low for six, and very low for nine.

Conclusion

Autogenous bone remains the volumetric reference standard. The improvement in graft success with platelet-rich fibrin was supported by moderate-certainty evidence and persisted across all sensitivity analyses, including restriction to randomized evidence. The concentrated growth factor finding had low certainty, relied on one retrospective study, and did not persist when analyses were restricted to radiographic outcomes. Adequately powered randomized trials with standardized methods are needed.

INTRODUCTION

Cleft lip and palate affects about 1 in 700 live births globally, with higher prevalence in Asian populations and males [1,2]. Its multifactorial etiology includes genetic susceptibility and maternal exposures such as smoking, whose association with nonsyndromic clefts is particularly pronounced in Asian populations [3]. About three-quarters of affected patients have an alveolar cleft [4]. Reconstruction aims to restore maxillary arch continuity and stability, separate the nasal and oral cavities, and support adjacent teeth and the nasal base [4]. Secondary alveolar bone grafting, introduced by Boyne and Sands, is standard care during mixed dentition before permanent canine eruption; timing is guided by canine root development rather than age [4-6]. This timing supports spontaneous canine eruption into the graft and subsequent orthodontic space closure [5].

The anterior iliac crest is the most common donor site and the gold standard for alveolar cleft repair, supplying abundant osteogenic, osteoinductive, and osteoconductive cancellous bone [7,8]. Donor-site morbidity is its main drawback: in a longitudinal study, 87% of patients reported pain at 1 week, 18% had hematoma, and 22% had sensory nerve injury; chronic pain persisted in 60% at 1 month but subsided by 3 months [9]. Cleft series report donor-site complication rates of roughly 5%–10% [7]. Bone availability is finite, and iliac cancellous grafts can undergo 30%–55% resorption within 6 months, sometimes requiring regrafting [10]. Bergland-scale failure rates range from about 8% to 18% in contemporary cohorts [11], and the reconstructed cleft side retains significantly less bone than the non-cleft side long term [8]. Additional operative time further motivates the search for alternatives.

Regenerative agents augment or replace autogenous bone by supplying osteoinductive signals or osteogenic cells. Recombinant human bone morphogenetic protein-2 (rhBMP-2) recruits osteoprogenitor cells and promotes their differentiation into bone. Pediatric series report bone formation and clinical success comparable to iliac crest grafting without a second surgical site, but no significant advantage over autograft [12]. Platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and concentrated growth factor (CGF) are autologous centrifuged blood products that release bone-healing growth factors. Added to autogenous bone to accelerate healing, they have not consistently increased bone formation or density in comparative trials [13]. Bone marrow aspirate concentrate (BMAC) and mesenchymal or adipose-derived stem cells, including the stromal vascular fraction (SVF), supply osteogenic cells that differentiate toward osteoblasts; early trials yielded bone volumes comparable to autograft [14,15]. Tissue engineering combines these signals and cells with bioactive or three-dimensional (3D) printed scaffolds [16].

Most studies compare one agent with autogenous bone, and meta-analyses have evaluated single materials or groupings: one found no significant graft-volume difference between autogenous bone and alloplastic substitutes [17]; another assessed autogenous bone with substitutes, substitutes alone, and iliac crest graft against the iliac crest reference [18]. None has simultaneously compared and ranked the full range of regenerative agents. Network meta-analysis combines direct and indirect evidence through a common comparator to compare treatments never tested head to head [19] and rank them [20,21]. This review compared regenerative agents with one another and autogenous bone, ranking them for new bone formation, bone density, graft volume, and graft success in alveolar cleft reconstruction.

METHODS

Protocol and registration

This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement [22] and network meta-analysis extension [23]. The protocol was registered in PROSPERO (CRD420261432210).

Eligibility criteria

Eligibility was defined a priori using the population, intervention, comparison, outcomes, and study design (PICOS) framework. Eligible studies enrolled patients undergoing secondary alveolar cleft bone grafting, compared a regenerative agent alone or with autogenous bone against autogenous bone graft, and reported at least one bone-formation or graft-success outcome for two or more groups (Table 1). Four mutually exclusive outcomes were defined: new bone formation (percentage bone fill or bone formation ratio), graft volume (absolute volume in mm³ or cm³), bone density (Hounsfield units or equivalent radiographic density), and graft success (Bergland or Chelsea scale, or equivalent clinical definition). When multiple metrics were eligible, a prespecified hierarchy assigned a single metric to a single network; networks were analyzed separately. Analyses used absolute values at the follow-up closest to 6 months, or change-from-baseline values when exclusively reported. Supplementary Table 1 lists network assignments. For Yadav et al. [24], bone density was averaged across the coronal, middle, and apical thirds, as defined by the original authors.

Eligibility criteria by population, intervention, comparison, outcomes, and study design

Information sources and search

PubMed, Embase, the Cochrane Library, Scopus, ScienceDirect, and Web of Science were searched from January 2000 to June 30, 2026, for English-language human studies. The start date reflected the agents’ introduction into clinical use. Searches combined cleft population, alveolar bone grafting, and regenerative agents with AND, omitting outcomes to preserve sensitivity; reference lists of included studies and relevant reviews were hand-searched. Before deduplication, 1,228 records were retrieved: PubMed, 244; Embase, 188; Cochrane Library, 68; Scopus, 272; ScienceDirect, 208; and Web of Science, 248.

Study selection

Two reviewers independently screened titles, abstracts, and then full texts against eligibility criteria, resolving disagreements through discussion or a third reviewer. The PRISMA flow diagram summarizes selection (Fig. 1).

Fig. 1.

Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 flow diagram of study identification, screening, and inclusion. Six databases yielded 1,228 records, of which 21 studies (23 reports) met the eligibility criteria. Sixteen studies were eligible for quantitative synthesis, and five were reserved for prespecified sensitivity analyses.

Data extraction

Two reviewers independently extracted study and patient characteristics, interventions, comparators, outcomes, and followup using a piloted standardized form. Discrepancies were checked against source articles and resolved by consensus.

Risk of bias assessment

Two reviewers independently assessed bias using version 2 of the Cochrane risk-of-bias tool (RoB 2) [25] for randomized trials and the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool [26] for nonrandomized comparative studies, resolving disagreements through discussion.

Data synthesis and network meta-analysis

Estimates were reported with 95% confidence intervals (CIs). Continuous outcomes (percentage bone fill, graft volume, and bone density) were expressed as mean differences or standardized mean differences (SMDs) when scales differed; dichotomous outcomes (graft success and complications) were expressed as odds ratios or risk ratios (RRs). Outcomes without a common metric were summarized narratively.

Pairwise random-effects meta-analysis using restricted maximum likelihood was performed for each comparison with at least two studies, with heterogeneity quantified by I² and the between-study variance τ². A frequentist random-effects network meta-analysis combined direct and indirect evidence using autogenous bone graft as the common reference. Agents were ranked by P-score, the frequentist analogue of the surface under the cumulative ranking curve, using the NetMetaEasy module of MetaAnalysisOnline.com [27,28]. For three-arm trials contributing a shared control group to two active-treatment comparisons in one network, the standard method to avoid double-counting was applied: the shared group was divided proportionally according to the original per-arm allocation before pooling. In the study by Yadav et al. [24], the autograft arm (n=25) was split between the PRF comparison (n=13) and the PRP comparison (n=12), matching the active arms’ respective original sample sizes (n=13 and n=12). Transitivity was assessed by tabulating potential effect modifiers across studies in each network: age, dentition stage, cleft type, donor site, graft form, imaging modality, follow-up interval, and unit of analysis (Supplementary Table 2). Because most contrasts relied on only one or two trials, transitivity was assessed clinically and could not be tested statistically. Where a closed loop was present, consistency was assessed by node-splitting [29] and the design-by-treatment interaction model, although the largely star-shaped networks limited formal inconsistency testing.

Primary networks included only studies eligible for quantitative synthesis. Overlapping Children’s Hospital Los Angeles (CHLA) reports [30-32] were treated as one cohort to avoid double-counting. Five studies outside the agent-versus-autograft comparison [33-37] were held out. Four sensitivity analyses were prespecified: (1) randomized controlled trials only, excluding studies at serious ROBINS-I risk; (2) reintroduction of studies [33,34]; (3) reintroduction of studies [35-37] as a substitute-plus-concentrate subgroup; and (4) replacement of the overlapping cluster with its largest report. Comparison-adjusted funnel plots explored small-study and publication bias when sufficient studies were available.

Certainty was assessed using the Grading of Recommendations Assessment, Development and Evaluation approach for network meta-analysis and six Confidence in Network Meta-Analysis domains: within-study bias, reporting bias, indirectness, imprecision, heterogeneity, and incoherence (Table 2, Supplementary Table 3). Incoherence was assessable only for the rhBMP-2 contrasts in the new-bone-formation network, containing the only closed loop (node-split p=0.69); unassessable domains did not trigger downgrading. Reporting bias was not formally tested because each comparison included fewer than 10 studies. Three post hoc sensitivity analyses requested during peer review were exploratory: restriction of graft success to radiographic outcomes, exclusion of Chen et al. [38] from graft volume, and exclusion of Eid et al. [39] from bone density.

Certainty of evidence for each network estimate

RESULTS

Study selection

The six-database search identified 1,228 records, and hand-searching reference lists or trial registers yielded no additional records. After removal of 696 duplicates, 532 records underwent title and abstract screening, and 481 were excluded as clearly irrelevant. Fifty-one reports were sought; two could not be retrieved, leaving 49 for full-text eligibility assessment. At this stage, 26 reports were excluded: 11 were noncomparative, nine had an ineligible intervention or outcome, and six described overlapping cohorts or conference abstracts. The remaining 23 reports represented 21 included studies because three reports from the CHLA series [30-32] were treated as one study to avoid double-counting patients. Of these studies, 16 were eligible for quantitative synthesis (Table 3), and five were reserved for prespecified sensitivity analyses (Table 4). Three of the 16 could not connect to any outcome network: Kahan et al. [40] defined success as the clinical need for regrafting rather than using the Bergland or Chelsea scale and reported volumetric outcomes as medians with interquartile ranges; Desai et al. [41] included BMAC in both arms and had no autograftalone comparator; and Kurimori et al. [42] reported SVF outcomes that could not be expressed on a common scale with other trials. Fig. 1 summarizes selection in the PRISMA 2020 flow diagram.

Characteristics of the 16 studies eligible for quantitative synthesis

Studies reserved for sensitivity analyses

Study characteristics

The studies were published from 2011 to 2026 and conducted in several countries, most commonly Egypt, India, the United States, and China. Designs included randomized controlled trials and nonrandomized comparative cohorts, most of the latter retrospective. Participants were predominantly children and adolescents with mixed dentition and mean ages of approximately 8–13 years; one trial enrolled adults, and both unilateral and bilateral alveolar clefts were represented. Agents included PRF, PRP, CGF, rhBMP-2, BMAC, SVF, and tissue-engineered or stem-cell constructs, each compared with autogenous bone graft, usually from the anterior iliac crest. Follow-up ranged from 3 months to several years, with bone outcomes assessed by cone-beam computed tomography (CBCT), conventional computed tomography, or two-dimensional (2D) radiography. Tables 3 and 5 present full study and outcome details.

Outcome data and the metric entered into each network

Studies reserved for sensitivity analyses

Five broadly eligible studies were reserved a priori for sensitivity analyses because their comparisons differed from agent versus autograft. Table 4 summarizes their designs, interventions, and reasons for exclusion from primary networks.

Risk of bias

Risk of bias was assessed in all 21 included studies, using RoB 2 for the 14 randomized trials and ROBINS-I for the seven nonrandomized comparative studies. Six randomized trials were rated at high risk, and seven raised some concerns, chiefly because random-sequence generation and allocation concealment were incompletely reported and blinding of surgeons and, often, outcome assessors was not feasible. Shabaan et al. [45] was the only randomized trial rated at low overall risk. Dayashankara Rao et al. [46] was rated at high risk because allocation alternated between odd and even sequences, a predictable, nonrandom method without concealment. In Thanasut et al. [50], 35% of enrolled participants were lost before analysis (20 recruited, 13 analyzed), creating an additional missing-data concern. Kurimori et al. [42] had marked baseline differences in age and cleft size, but robust block randomization with sequentially sealed envelopes suggested chance imbalance in a small sample; nevertheless, the trial was rated at high risk because the authors stated that the same investigator and surgeon collected data without blinding. Six nonrandomized studies were rated at serious risk and one at moderate risk, mainly because of confounding by indication and selection effects. Trujillo et al. [49] excluded 85 of 110 patients, primarily for incomplete records or imaging from a different scanner, and imaging intervals differed by roughly 9 months between arms. Balaji [48] reported implausibly narrow standard deviations and used unblinded 2D planimetry. Both studies were rated at serious risk. Among the five studies reserved for sensitivity analyses, two of the four randomized trials raised some concerns [35,36], mainly because allocation concealment was not described. Aldaghir et al. [34] was rated at high risk because allocation used a coin toss, participants lost to follow-up were excluded, and the reported test statistic and standard deviations were incompatible. Bajestan et al. [33] was rated at high risk because enrollment in the cleft cohort stopped early on the basis of observed outcomes and no inferential statistics were reported. The retrospective study, Seif [37], was rated at serious risk owing to confounding by indication. Risk of bias did not determine exclusion; instead, the prespecified randomized-trials-only sensitivity analysis tested the influence of higher-risk nonrandomized studies. Domain-level judgments and their summary distributions were visualized using robvis (Fig. 2A and B for the 14 randomized trials; Fig. 2C and D for the seven nonrandomized studies) [52].

Fig. 2.

Risk-of-bias assessment generated using robvis. (A, B) RoB 2 traffic-light plot and weighted summary bar plot for the 14 randomized trials. (C, D) ROBINS-I traffic-light plot and weighted summary bar plot for the seven nonrandomized studies. The CHLA row represents the pooled Francis (2013) [32], Liang (2017) [31], and Hammoudeh (2017) [30] cohort, assessed using the index report. Green indicates low risk; yellow, some concerns (RoB 2) or moderate risk (ROBINS-I); and red, high risk (RoB 2) or serious risk (ROBINS-I). RoB 2, Cochrane risk-of-bias tool for randomized trials, version 2; ROBINS-I, Risk Of Bias In Non-randomized Studies of Interventions; CHLA, Children’s Hospital Los Angeles.

Network geometry

All four networks were predominantly star-shaped, with autogenous bone graft as the central comparator and only indirect connections between agents through this reference.

• New bone formation (primary outcome): the five-node network comprised autograft, PRF, PRP, rhBMP-2, and rh- BMP-2 with zygomatic shavings. The three-arm study [48] supplied its single closed loop; every other agent connected only through autograft.

• Bone density: within-design heterogeneity (Q and df) could not be estimated because, apart from the three-arm trial incorporated using the split-control method, each direct comparison was informed by only one study. The five-node network comprised autograft, PRF, PRP, BMAC, and the tissue-engineered or stem-cell construct, with no closed loop. The PRF and PRP arms entered through the three-arm trial [24], using the split-control method.

• Graft volume: within-design heterogeneity (Q and df) could not be estimated because each direct comparison was informed by only one study. The four-node star comprised autograft, BMAC, PRP, and the tissue-engineered construct. It had no closed loop, and each agent was linked to autograft by one trial.

• Graft success: the five-node network comprised autograft, PRF, CGF, rhBMP-2, and PRP, with no closed loop. PRP connected only through study [24].

Fig. 3 shows the four networks, with agent comparisons largely indirect through autograft.

Fig. 3.

Network geometry by outcome. Nodes represent treatments, and edges represent direct comparisons. Node size reflects the number of patients or, for graft success, the contributing study’s analysis unit (patients, cleft sides, or graft exposures; see Results); edge labels indicate the number of studies. (A) New bone formation; (B) bone density; (C) graft volume; (D) graft success. Autogenous bone graft is the common reference. PRP, platelet-rich plasma; rhBMP-2, recombinant human bone morphogenetic protein-2; PRF, platelet-rich fibrin; BMAC, bone marrow aspirate concentrate; TE, tissue-engineered construct; CGF, concentrated growth factor.

Network meta-analysis findings

Primary outcome: new bone formation

Five studies contributed to this network (153 patients; seven pairwise comparisons). Every agent had a point estimate favoring greater bone formation than autograft, but none was significant: rhBMP-2 with zygomatic shavings (SMD, 1.77; 95% CI, −0.36 to 3.90), PRF (SMD, 1.21; 95% CI, −0.44 to 2.87), PRP (SMD, 0.30; 95% CI, −1.87 to 2.48), and rhBMP-2 alone (SMD, 0.08; 95% CI, −1.48 to 1.63). Fig. 4A presents the forest plot.

Fig. 4.

Forest plots of network meta-analysis estimates for each treatment versus autogenous bone graft, ordered by P-score. (A) New bone formation (SMD); (B) bone density (SMD); (C) graft volume (SMD); (D) graft success (RR). Squares indicate point estimates, and horizontal lines indicate 95% CIs. SMD, standardized mean difference; RR, risk ratio; CI, confidence interval; rhBMP-2, recombinant human bone morphogenetic protein-2; PRF, platelet-rich fibrin; PRP, platelet-rich plasma; BMAC, bone marrow aspirate concentrate; TE, tissue-engineered construct; CGF, concentrated growth factor.

Secondary outcome: bone density

Four studies contributed to the bone-density network (145 patients; five pairwise comparisons). The three-arm trial [24], which provided no direct PRF-versus-PRP comparison, was incorporated using the Cochrane split-control method, dividing its autograft arm between the two active comparisons. PRF (SMD, 3.15; 95% CI, −3.56 to 9.86), PRP (SMD, 3.15), and BMAC (SMD, 3.03) had large point estimates favoring greater density than autograft, whereas the tissue-engineered construct did not (SMD, −0.61). All CIs were wide and crossed the null, and no comparison was significant. Fig. 4B presents the forest plot.

Secondary outcome: graft volume

Three studies contributed to the graft-volume network (86 patients; three pairwise comparisons). BMAC produced significantly greater graft volume than autograft (SMD, 2.36; 95% CI, 1.51 to 3.21), whereas PRP (SMD, 0.52; 95% CI, −0.11 to 1.15) and the tissue-engineered construct (SMD, 0.12; 95% CI, −1.12 to 1.37) did not differ significantly from autograft. Network estimates also favored BMAC over PRP (SMD, 1.84; 95% CI, 0.78 to 2.89) and the tissue-engineered construct (SMD, 2.23; 95% CI, 0.73 to 3.74). Fig. 4C presents the forest plot.

Secondary outcome: graft success

The graft-success network comprised five studies and 756 analysis units, rather than 756 individual patients. It combined three units of analysis: 191 patients analyzed individually (n=75 across three arms [24], n=86 [51], n=30 [46]); 95 cleft sides with adequate postoperative imaging from 130 treated patients [43]; and 470 graft exposures from 414 patients in the CHLA cohort [30], reflecting grafting at more than one cleft site in some patients. None of the five source reports linked site- or exposure-level identifiers to shared patients, so within-patient clustering could not be adjusted for and must be considered when interpreting network estimates. Six pairwise comparisons were possible, with Yadav’s three-arm trial [24] incorporated using the Cochrane split-control method. Graft success was expressed as an RR. Compared with autograft, PRF significantly increased the probability of graft success (RR, 1.46; 95% CI, 1.07–2.01), as did CGF (RR, 1.21; 95% CI, 1.02–1.43). PRP (RR, 1.30; 95% CI, 0.77–2.21) and rhBMP-2 (RR, 1.02; 95% CI, 0.96–1.08) did not differ significantly from autograft. The network estimate also favored PRF over rhBMP-2 (RR, 1.44; 95% CI, 1.04–1.99). Node-splitting confirmed that all four agent-versus-autograft contrasts relied solely on direct evidence, whereas all six agent-versus-agent contrasts, including PRF versus rhBMP-2, relied entirely on indirect evidence (Supplementary Table 4). Fig. 4D presents the forest plot.

Treatment ranking

Primary outcome

P-scores ranked rhBMP-2 with zygomatic shavings first (0.84), followed by PRF (0.71), PRP (0.40), rhBMP-2 alone (0.30), and autograft (0.25). All comparisons were nonsignificant, and the leading estimate came from one small study; the ranking is therefore hypothesis-generating rather than confirmatory.

Secondary outcome: graft volume

BMAC ranked first for graft volume by P-score (1.00), followed by PRP (0.55), the tissue-engineered construct (0.29), and autograft (0.16). As this ranking rests on a single small trial [45], it should be regarded as hypothesis-generating.

Secondary outcome: graft success

PRF ranked first for graft success by P-score (0.87), followed by PRP (0.66), CGF (0.62), rhBMP-2 (0.23), and autograft (0.12). Unlike the volume and density outcomes, PRF and CGF exhibited statistical significance against autograft, making this ranking more than hypothesis-generating, although the PRP estimate was very imprecise and came from one trial.

Inconsistency, heterogeneity, and sensitivity

Primary outcome

Within-design heterogeneity was high (I²=86.2%; 95% CI, 60.2–95.2; Q= 13, df= 1, p<0.001), consistent with pooling different volumetric and densitometric scales as SMDs. No inconsistency was detected (design-by-treatment Q p=0.218; nodesplit p=0.69 for the only closed loop). The comparison-adjusted funnel plot and Egger test (p=0.68) showed no asymmetry (Fig. 5A), although the small number of studies limited power. Balaji’s retrospective study [48], with its narrow standard deviations, inflated both heterogeneity and the leading rank; the prespecified randomized-trials-only analysis was therefore expected to provide the most informative sensitivity check.

Fig. 5.

Comparison-adjusted funnel plots by outcome. (A) New bone formation; (B) bone density; (C) graft volume; (D) graft success. These plots are exploratory because every comparison included fewer than 10 studies; a formal Egger test is reported only for the primary outcome (p=0.68). PRF, platelet-rich fibrin; PRP, platelet-rich plasma; rhBMP-2, recombinant human bone morphogenetic protein-2; BMAC, bone marrow aspirate concentrate; TE, tissue-engineered construct; CGF, concentrated growth factor.

Secondary outcome: bone density

Yadav et al. [24] dominated these estimates because its unusually narrow standard deviations—coefficients of variation of approximately 4%–5%, compared with 12%–37% in other trials—gave it substantial weight. Excluding Yadav in a prespecified sensitivity analysis reduced the network to three studies (70 patients) and removed the PRP node, which that study alone had informed. In the reduced network, the PRF estimate reversed toward the null (SMD, −0.23; 95% CI, −1.04 to 0.57), and only BMAC remained significant (SMD, 3.03; 95% CI, 2.07–3.99), on the basis of one trial [45]. The density ranking was therefore not robust and depended heavily on one study. A comparison-adjusted funnel plot is provided for completeness (Fig. 5B), but publication bias was not formally assessed because every comparison included fewer than 10 studies.

Secondary outcome: graft volume

Because the graft-volume network was a pure star without a closed loop, inconsistency between direct and indirect evidence could not be assessed. A comparison-adjusted funnel plot is provided for completeness (Fig. 5C); publication bias was again not formally assessed because there were fewer than 10 studies. The only significant result, BMAC versus autograft, came from one small randomized trial [45]. Wide CIs for the other agents reflect very small samples, particularly the five-patient tissue-engineering trial. These estimates therefore require cautious interpretation.

Secondary outcome: graft success

Within-design heterogeneity was negligible (I²=0%; 95% CI, 0–89.6; Q= 0.1, df= 2, p=0.937), making graft success the most stable network examined. Its pure-star structure, without a closed loop, prevented assessment of inconsistency between direct and indirect evidence. A comparison-adjusted funnel plot is provided for completeness (Fig. 5D); publication bias was again not formally assessed because there were fewer than 10 studies. Yadav et al. [24] used the stricter Bergland type I definition of success and was incorporated using the split-control method. Its exclusion in a prespecified sensitivity analysis reduced the network to four studies (681 patients) and removed the PRP node, which it alone had informed. The principal finding remained robust: PRF (RR, 1.56; 95% CI, 1.01–2.40) and CGF (RR, 1.21; 95% CI, 1.02–1.43) remained significantly superior to autograft, with negligible heterogeneity (I²= 0%, Q=0, df=1, p=0.974). The only material change was that PRF was no longer significantly superior to rhBMP-2 (RR, 1.53; 95% CI, 0.99–2.37); the PRF estimate now rested on one trial [46].

Restricting the new-bone-formation network to randomized trials in the prespecified sensitivity analysis left three trials (79 patients) and removed both rhBMP-2 nodes. Point estimates were essentially unchanged for PRF (SMD, 1.23; 95% CI, −1.46 to 3.91) and PRP (SMD, 0.30; 95% CI, −3.40 to 4.00), but CIs widened and no comparison was significant. The primary analysis’s leading treatment, rhBMP-2 with zygomatic shavings, disappeared because it relied entirely on one retrospective study at serious risk of bias; PRF then ranked first (P-score, 0.73). Removal of the review’s only closed loop also prevented further assessment of inconsistency. The graft-success network was reduced to two trials (105 patients), losing the rhBMP-2 and CGF nodes, but PRF remained significantly superior to autograft with an unchanged estimate (RR, 1.46; 95% CI, 1.07 to 2.01; I²=0%). Replacing the CHLA cluster with its largest report did not change this network because the cluster’s success data already came from the index report [30]. Neither Bajestan et al. [33] nor Aldaghir et al. [34] could be reintroduced into any network: Bajestan et al. [33] reported horizontal ridge width gain in millimeters, which was not compatible with the analyzed outcome metrics, and both arms in Aldaghir et al. [34] received autogenous bone, so the contrast concerned bone source rather than agent versus autograft. Studies [35-37] each reported different outcomes and could not be pooled as a single substitute-plus-concentrate subgroup; all three are summarized narratively.

Three additional sensitivity analyses were performed post hoc. Restricting graft success to radiographic definitions left three studies (200 patients) and removed the CGF node; PRF remained significantly superior to autograft (RR, 1.46; 95% CI, 1.07–2.01) and rhBMP-2 (RR, 1.44; 95% CI, 1.02–2.04). Excluding Chen et al. [38] from the graft-volume network left every estimate unchanged. Excluding Eid et al. [39] from the bone-density network left each contrast informed by one trial, forcing the between-study variance to zero and narrowing all intervals to within-study precision alone; the PRF estimate rose to SMD 6.61 (95% CI, 4.96–8.27). This apparent improvement in precision is a structural artifact of removing all replication, not evidence of a stronger effect (Supplementary Table 5).

Certainty of evidence

Evidence certainty was moderate for one contrast, low for six, and very low for the other nine (Table 2). PRF versus autograft for graft success was the only estimate not downgraded for imprecision, heterogeneity, or indirectness; it was downgraded once for within-study risk of bias, and its estimate was unchanged across all sensitivity analyses, including restriction to randomized evidence alone. All four new-bone-formation contrasts and three of the four bone-density contrasts had very low certainty because of wide CIs, high statistical heterogeneity, and reliance on single small studies.

DISCUSSION

PRF (RR, 1.46; 95% CI, 1.07–2.01) and CGF (RR, 1.21; 95% CI, 1.02–1.43) significantly improved graft success over autograft. PRF ranked highest (P-score, 0.87) and exceeded rhBMP-2 (RR, 1.44; 95% CI, 1.04–1.99). No agent significantly improved new bone formation or bone density. Only BMAC increased graft volume, based on one small trial (SMD, 2.36; 95% CI, 1.51–3.21; P-score, 1.00). These findings support platelet concentrates as adjuncts, with autogenous bone remaining the volumetric reference standard (Fig. 6).

Fig. 6.

Heatmap of treatment rankings (P-scores) across four outcomes. Higher P-scores, shown in green, indicate higher rank; color represents rank, not statistical significance. Asterisks identify treatments significantly superior to autogenous bone graft, the common reference. PRF, platelet-rich fibrin; NR, treatment not connected in that outcome network; CGF, concentrated growth factor; PRP, platelet-rich plasma; BMAC, bone marrow aspirate concentrate; TE, tissue-engineered; MSC, mesenchymal stem cell; rhBMP-2, recombinant human bone morphogenetic protein-2.

The graft-success findings differed in robustness. PRF remained significant with moderate certainty in every sensitivity analysis: RR 1.46 in both the full network (five studies, 756 analysis units) and the randomized-trials-only network (two trials, 105 patients), increasing to 1.56 after excluding Yadav et al. [24]. The low-certainty CGF estimate came from one retrospective study defining success as absence of sequestrum and oronasal fistula; the node disappeared with restriction to randomized or radiographic evidence. In that study, Lai et al. [51], CGF was placed on the nasal and labial surfaces, and bone resorption did not differ between groups.

PRF and CGF contain a 3D fibrin scaffold that releases bonehealing growth factors—including platelet-derived growth factor, transforming growth factor beta, and vascular endothelial growth factor—as fibrin degrades over 1–2 weeks (Fig. 7) [53,54]. These factors recruit mesenchymal stem cells and osteoblasts and promote osteogenic differentiation through Smad and Wnt signaling; vascular endothelial growth factor also couples angiogenesis to osteogenesis and supports early graft vascularization [53,55]. CGF forms a denser matrix, promotes osteogenic differentiation, and directs macrophages toward a proregenerative phenotype [55,56]. These mechanisms may favor grafting reliability over absolute bone volume [57].

Fig. 7.

Biological mechanisms of regenerative agents in secondary alveolar cleft grafting. Autogenous bone provides the osteogenic, osteoinductive, and osteoconductive reference standard. rhBMP-2 drives osteoblast differentiation through Smad signaling; platelet concentrates (PRF, CGF, and PRP) release bone-healing growth factors; and BMAC supplies osteogenic cells. These pathways converge on osteoblast activity, angiogenesis, new bone formation, and graft consolidation. rhBMP-2, recombinant human bone morphogenetic protein-2; PRF, platelet-rich fibrin; CGF, concentrated growth factor; PRP, platelet-rich plasma; BMAC, bone marrow aspirate concentrate; DBM, demineralized bone matrix; βTCP, beta-tricalcium phosphate; HA/TCP, hydroxyapatite/tricalcium phosphate; BMP, bone morphogenetic protein; FDA, Food and Drug Administration; PDGF, platelet-derived growth factor; TGF-β, transforming growth factor beta; VEGF, vascular endothelial growth factor; BM-MSC, bone marrow-derived mesenchymal stem cell.

rhBMP-2 estimates were close to those for autograft, with a low graft-success ranking (P-score, 0.23; nonsignificant RR, 1.02); PRF outperformed it (RR, 1.44; 95% CI, 1.04–1.99). Pediatric meta-analyses likewise found no clear advantage over autograft, and a pairwise synthesis found greater bone formation with autogenous bone at 6 months [12,58]. Postoperative swelling and edema are the main pediatric complications, and the Food and Drug Administration has warned of life-threatening airway edema [12,58]. Complications increase with dose, favoring low doses of about 0.5–0.7 mg per level [59,60]. Despite higher material costs, demineralized bone matrix with rhBMP-2 was more cost-effective than iliac crest grafting for alveolar clefts (US$4,836 vs. US$6,892), owing to shorter operations and same-day discharge [61]. BMAC’s volume gain rests on one small trial and cannot yet support routine recommendation.

Divergent graft-success and volumetric findings partly reflect inconsistent success definitions. A scoping review identified 20 nonradiographic, 2D, and 3D scoring scales; none captures every surgical goal [62]. Bergland and Chelsea scales cannot measure depth and may classify an apical defect with normal interdental height as successful [62]. Volumetric CBCT avoids distortion and superimposition and has high measurement reliability [63], but lacks standardized landmarks, protocols, and timing [64,65]. Graft resorption can approach half the implanted volume within 6 months [64]. Measurement variation may contribute to heterogeneity; standardized CBCT workflows with automated segmentation are emerging to reduce observer variability [64,66].

Earlier pairwise reviews separately evaluated platelet concentrates with autogenous bone [67], stem-cell or tissue-engineered constructs versus scaffold or autograft [68], and bovine xenograft versus iliac bone [69]; broader appraisals retained autogenous bone as the volumetric gold standard [70]. Network meta-analysis enables simultaneous treatment ranking despite scarce head-to-head trials, as demonstrated for bone substitutes in sinus augmentation [71].

To our knowledge, this is the first network meta-analysis to rank the full range of regenerative agents against autogenous bone for alveolar cleft reconstruction, with prespecified sensitivity analyses and two risk-of-bias tools covering all studies [72]. However, few studies informed each comparison, and samples were small. Predominantly star-shaped networks limited head-to-head evidence, leaving agent comparisons largely indirect and transitivity untestable [73,74]. With one or two trials per contrast, heterogeneity increases realized error and can produce inconsistency despite exchangeability [75]. Continuous outcomes had high heterogeneity because different volumetric and densitometric scales were combined as SMDs; one trial with implausibly narrow standard deviations dominated density estimates, and among the trials contributing to the continuous-outcome analyses, most raised some concerns or had a higher risk of bias, with two rated at high risk. Rankings must therefore be considered alongside evidence certainty [76]. PRF’s bone-density SMD shifted from −0.23 after excluding Yadav et al. [24] to 3.15 in the primary analysis, to 6.61 after excluding Eid et al. [39], without changes to underlying trial data. P-scores are relative rankings within a network, not effect sizes. Effect modifiers differed: Eid et al. [39] used mandibular symphysis rather than iliac crest; Lai et al. [51] used a corticocancellous block with titanium fixation, whereas other autograft arms used particulate bone; and analysis units included patients, cleft sites, clefts, and graft exposures without clustering adjustment (Supplementary Table 2). Outcome definitions, imaging, and follow-up varied; several estimates depended on single trials or three-arm trials analyzed using split controls.

Platelet concentrates improve grafting reliability and may shorten healing but lack the structural scaffold to maintain volume in large defects, supporting their use to augment rather than replace autogenous bone [77,78]. Adequately powered randomized trials should compare agents with one another and autograft using standardized CBCT volumetric endpoints, graft-success definitions, and platelet-concentrate protocols [64,77]. Consistent reporting of harms, donor-site morbidity, long-term outcomes, and pediatric safety is needed, particularly given the scarcity and geographic concentration of registered alveolar bone-grafting trials [78].

Seif [37] reported autograft-arm values identical to those in Shawky and Seifeldin [47], despite a different sample size and follow-up interval; the reports also shared an author and institution. Possible cohort overlap could not be excluded, so Seif [37] was retained only in the substitute-plus-concentrate sensitivity analysis and did not contribute to any primary network.

CONCLUSION

Autogenous bone graft remains the reference standard for alveolar cleft reconstruction; no regenerative agent produced significantly more new bone. PRF significantly improved graft success with moderate-certainty evidence, and this finding persisted across all sensitivity analyses, including restriction to radiographically defined outcomes and randomized evidence alone. CGF also improved graft success, but the low-certainty estimate came from one retrospective study with a clinical definition of success and did not persist when analysis was restricted to radiographic outcomes. Given the limited and largely indirect evidence, these findings remain hypothesis-generating and require confirmation in adequately powered randomized trials with standardized methods.

Notes

Conflict of interest

No potential conflict of interest relevant to this article was reported.

Funding

None.

Author contributions

Conceptualization: Muhammad Irpan Hendrawan, Andi Tajrin. Data curation: Muhammad Irpan Hendrawan, Andi Arfandi Arifuddin, Hadira Hadira. Formal analysis: Muhammad Irpan Hendrawan, Husni Mubarak. Investigation: Muhammad Irpan Hendrawan, Andi Arfandi Arifuddin, Hadira Hadira, Nurwahida Nurwahida. Methodology: Muhammad Irpan Hendrawan, Husni Mubarak, Irham Taufiqurrahman, Muhammad Irfan Rasul, Andi Tajrin. Visualization: Nurwahida Nurwahida, Nining Dwi Suti Ismawati. Supervision: Andi Tajrin. Validation: Irham Taufiqurrahman. Writing−original draft: Muhammad Irpan Hendrawan. Writing−review & editing: Husni Mubarak, Muhammad Irfan Rasul, Irham Taufiqurrahman, Nining Dwi Suti Ismawati, Andi Tajrin. All authors read and approved the final manuscript.

Supplementary materials

Supplemental data can be found at: https://doi.org/10.7181/acfs.2026.0106.

Supplementary Table 1.

Assignment of each study to each outcome network

acfs-2026-0106-Supplementary-Table-1.xlsx
Supplementary Table 2.

Distribution of potential effect modifiers across contributing studies

acfs-2026-0106-Supplementary-Table-2.xlsx
Supplementary Table 3.

Certainty of evidence by Confidence in Network Meta-Analysis domain

acfs-2026-0106-Supplementary-Table-3.xlsx
Supplementary Table 4.

League table and node-splitting for the graft-success network

acfs-2026-0106-Supplementary-Table-4.xlsx
Supplementary Table 5.

Summary of all sensitivity analyses

acfs-2026-0106-Supplementary-Table-5.xlsx

Abbreviations

2D

two-dimensional

3D

three-dimensional

ABG

autogenous bone graft

AIC

anterior iliac crest

AICBG

anterior iliac crest bone graft

A-PRF

advanced platelet-rich fibrin

BD6

bone density at 6 months

BMAC

bone marrow aspirate concentrate

BM-MSCs

bone marrow-derived mesenchymal stem cells

BV6

bone volume at 6 months

CBCT

cone-beam computed tomography

CGF

concentrated growth factor

CHLA

Children’s Hospital Los Angeles

CI

confidence interval

CL/P

cleft lip and/or palate

CT

computed tomography

DBM

demineralized bone matrix

DFDB

demineralized freeze-dried bone

HA

hydroxyapatite

HU

Hounsfield unit

ICBG

iliac crest bone graft

IOPA

intraoral periapical radiography

IQR

interquartile range

NS

not significant

OPG

orthopantomography

PCBM

particulate cancellous bone and marrow

PICOS

population, intervention, comparison, outcomes, and study design

PRF

platelet-rich fibrin

PRISMA

Preferred Reporting Items for Systematic Reviews and Meta-Analyses

PRP

platelet-rich plasma

RCT

randomized controlled trial

rhBMP-2

recombinant human bone morphogenetic protein-2

RoB 2

version 2 of the Cochrane risk-of-bias tool

ROBINS-I

Risk Of Bias In Non-randomized Studies of Interventions

RR

risk ratio

SD

standard deviation

SMD

standardized mean difference

SVF

stromal vascular fraction

TCP

tricalcium phosphate

TE

tissue- engineered construct

βTCP

beta-tricalcium phosphate

References

1. Tobgyel K, Rai P, Choden K, Gyeltshen T. Epidemiology of cleft lip and palate in Bhutan, 2015-2022. BMC Oral Health 2024;24:1385.
2. Putri FA, Pattamatta M, Anita SES, Maulina T. The global occurrences of cleft lip and palate in pediatric patients and their association with demographic factors: a narrative review. Children (Basel) 2024;11:322.
3. Vathulya M, Singh N, Naithani M, Kessler P. An intercontinental comparison of the influence of smoking on the occurrence of nonsyndromic cleft lip and palate: a meta-analysis and systematic review. Arch Craniofac Surg 2024;25:51–61.
4. Kim J, Jeong W. Secondary bone grafting for alveolar clefts: surgical timing, graft materials, and evaluation methods. Arch Craniofac Surg 2022;23:53–8.
5. Bartzela T, Hoffmann I, Kluge J, Jager F, Schmechel M, Opitz C. Timing matters: dental development and outcomes on secondary alveolar bone grafting in cleft lip and palate patients. Clin Oral Investig 2025;29:545.
6. Mink van der Molen AB, van Breugel JMM, Janssen NG, Admiraal RJC, van Adrichem LNA, Bierenbroodspot F, et al. Clinical practice guidelines on the treatment of patients with cleft lip, alveolus, and palate: an executive summary. J Clin Med 2021;10:4813.
7. Miguel-Escribano A, Galletti C, de Quixano-Bardaji J, Real-Voltas F, Fiorillo L, Cuevas-Nunez M, et al. Options for regenerative treatment with bone grafts in children with anterior lip/palate cleft: a review. Children (Basel) 2025;12:559.
8. Wursching T, Meszaros B, Solyom E, Molnar B, Bogdan S, Nemeth Z, et al. Long-term results of autologous tooth bone grafting in alveolar cleft reconstruction: a retrospective cohort study. Biomedicines 2025;13:1735.
9. Tahir B, Wahab NU, Memon MI, Fawad B. Donor site morbidity of iliac crest bone graft in maxillofacial surgery. J Coll Physicians Surg Pak 2025;35:28–32.
10. Weng L, Feng X, Wang Y, Shao J, Huang X, Han Y, et al. Designed guide plate assisted cortico-cancellous iliac crest bone grafting for alveolar cleft repair. BMC Oral Health 2025;25:1567.
11. Wu J, Zhuang J, Ma Y, Yin L, Wang Y. Risk factors associated with the failure of secondary alveolar bone grafting with autologous iliac crest bone in patients with alveolar cleft defects: a systematic review. Front Oral Health 2025;6:1640933.
12. Alawami EAA, Alomari F, Aloqaybi SA, Aloweiny Q, Alswayed LK, Alshafai NW, et al. Efficacy of recombinant human bone morphogenetic protein-2 in alveolar cleft treatment for children: systematic review and meta-analysis. Life (Basel) 2025;15:185.
13. Vasquez-Alvarez M, Wang Q, Zapata U. The use of platelet concentrates in the reconstruction of the alveolar cleft defect: a systematic review and meta-analysis. Cleft Palate Craniofac J 2025;62:633–52.
14. Li T, Wang YY, Li S, Hu Y, Sun Z, Liu C. Stem cell therapy’s efficiency in reconstructing alveolar clefts: a system review and meta-analysis of randomized controlled trials. Stem Cells Int 2025;2025:2780065.
15. Gu C, Tang Q, Li L, Chen Y. Optimization and implication of adipose-derived stem cells in craniofacial bone regeneration and repair. Bioengineering (Basel) 2024;11:1100.
16. Marian D, Toro G, D’Amico G, Trotta MC, D’Amico M, Petre A, et al. Challenges and innovations in alveolar bone regeneration: a narrative review on materials, techniques, clinical outcomes, and future directions. Medicina (Kaunas) 2025;61:20.
17. Putri IL, Fabian P, Wungu CDK. A meta-analysis of alveolar bone grafting using bone substitutes in cleft lip and palate patients. Tzu Chi Med J 2024;36:53–8.
18. Baghaei S, Feizbakhsh M, Attar BM, Khoshdel A, Abdali H. Autografts, bone substitutes, and combined approaches for secondary alveolar bone grafting: a systematic review and meta-analysis. J Oral Maxillofac Surg 2025;83:950–69.
19. Brignardello-Petersen R, Guyatt GH. Introduction to network meta-analysis: understanding what it is, how it is done, and how it can be used for decision-making. Am J Epidemiol 2025;194:837–43.
20. Salanti G, Nikolakopoulou A, Efthimiou O, Mavridis D, Egger M, White IR. Introducing the treatment hierarchy question in network meta-analysis. Am J Epidemiol 2022;191:930–8.
21. Nevill CR, Cooper NJ, Sutton AJ. A multifaceted graphical display, including treatment ranking, was developed to aid interpretation of network meta-analysis. J Clin Epidemiol 2023;157:83–91.
22. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
23. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777–84.
24. Yadav A, Borle R, Jajoo S, Jain A. Comparative evaluation of autologous bone grafting with and without PRP or PRF in cleft alveolus reconstruction: a prospective randomized study. Cleft Palate Craniofac J 2026;63:2736–43.
25. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898.
26. Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919.
27. Fekete JT, Komocsi A, Gyorffy B. NetMetaEasy: enabling rapid and user-friendly network meta-analysis (NMA) for comparative effectiveness research. Br J Pharmacol 2026;183:1814–23.
28. Fekete JT, Gyorffy B. MetaAnalysisOnline.com: web-based tool for the rapid meta-analysis of clinical and epidemiological studies. J Med Internet Res 2025;27e64016.
29. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932–44.
30. Hammoudeh JA, Fahradyan A, Gould DJ, Liang F, Imahiyerobo T, Urbinelli L, et al. A comparative analysis of recombinant human bone morphogenetic protein-2 with a demineralized bone matrix versus iliac crest bone graft for secondary alveolar bone grafts in patients with cleft lip and palate: review of 501 cases. Plast Reconstr Surg 2017;140:318e–325e.
31. Liang F, Yen SL, Imahiyerobo T, Sanborn L, Yen L, Yen D, et al. Three-dimensional cone beam computed tomography volumetric outcomes of rhBMP-2/demineralized bone matrix versus iliac crest bone graft for alveolar cleft reconstruction. Plast Reconstr Surg 2017;140:767–74.
32. Francis CS, Mobin SSN, Lypka MA, Rommer E, Yen S, Urata MM, et al. rhBMP-2 with a demineralized bone matrix scaffold versus autologous iliac crest bone graft for alveolar cleft reconstruction. Plast Reconstr Surg 2013;131:1107–15.
33. Bajestan MN, Rajan A, Edwards SP, Aronovich S, Cevidanes LHS, Polymeri A, et al. Stem cell therapy for reconstruction of alveolar cleft and trauma defects in adults: a randomized controlled, clinical trial. Clin Implant Dent Relat Res 2017;19:793–801.
34. Aldaghir OM, Naje AR, Ghadhban AT, Al Atabi HSH, Aldaghir OM. Effectiveness of maxillary cortical bone graft chips harvested by bone scraper, covered with platelet-rich fibrin (PRF), in reconstruction of alveolar clefts: comparative study. Oral Maxillofac Surg 2024;28:205–16.
35. Bedeer HM, Asklany A, Ali WM, Elyounsi M, Mohammed MNA, Youssef MM, et al. Outcomes of xenograft with platelet-rich fibrin versus autogenous bone in alveolar cleft grafting. Plast Reconstr Surg Glob Open 2024;12e6106.
36. Alnajjar A, Alkhoury I, Burhan AS, Alkhouli M. The efficacy of xenograft polymerized with platelet rich fibrin versus autogenous graft during the secondary alveolar bone grafting of alveolar clefts: a randomized controlled clinical trial. Int J Dent Oral Sci 2020;7:886–91.
37. Seif SA. Role of combination of particulated allograft and advanced platelet-rich fibrin (A-PRF) in alveolar cleft bone grafting: a comparative retrospective preliminary study. J Craniofac Surg 2026;37:e418–25.
38. Chen S, Liu B, Yin N, Wang Y, Li H. Assessment of bone formation after secondary alveolar bone grafting with and without platelet-rich plasma using computer-aided engineering techniques. J Craniofac Surg 2020;31:549–52.
39. Eid MK, Elsaadany WH, Ibrahim MT. Evaluation of platelet-rich fibrin versus collagen membrane for enhancing healing of secondary grafted alveolar cleft: a randomised controlled trial. Br J Oral Maxillofac Surg 2024;62:559–64.
40. Kahan RH, Palmer SK, Garoosi K, Gomez DA, Khechoyan DY, French B, et al. Alveolar bone grafting: outcomes utilizing synthetic HA/TCP and rhBMP-2 versus autologous graft types. Plast Reconstr Surg 2026;157:129–38.
41. Desai AK, Byadgi AA, Kumar N, Janardhan A, Manjunath T. Effect of “platelet rich” fibrin with bone marrow aspirate on the regenerative capacity of alveolar bone grafting with iliac bone graft: a randomized controlled trial. Natl J Maxillofac Surg 2024;15:460–6.
42. Kurimori KT, Bastos EO, Camara PRP, Mascarenhas Dias B, Uyeda GL, Alonso N. Alveolar bone graft supplemented with stromal vascular fraction in patients with permanent dentition: a randomized study. Cleft Palate Craniofac J 2026;63:133–43.
43. Lee KC, Costandi JJ, Carrao V, Eisig SB, Perrino MA. Autogenous iliac crest versus rhBMP-2 for alveolar cleft grafting: a 14-year single-institution experience. J Oral Maxillofac Surg 2021;79:431–40.
44. Kadry W, Eldeftar M, Nassar Y, Abou-El-Fetouh A, Hakam MM. Clinical, volumetric and densitometric evaluation of tissue engineered constructs for secondary alveolar cleft reconstruction: a randomized clinical trial. J Craniomaxillofac Surg 2021;49:1141–50.
45. Shabaan AA, Salahuddin A, Aboulmagd I, Ragab R, Salah KA, Rashid A, et al. Alveolar cleft reconstruction using bone marrow aspirate concentrate and iliac cancellous bone: a 12-month randomized clinical study. Clin Oral Investig 2023;27:6667–75.
46. Dayashankara Rao JK, Bhatnagar A, Pandey R, Arya V, Arora G, Kumar J, et al. A comparative evaluation of iliac crest bone graft with and without injectable and advanced platelet rich fibrin in secondary alveolar bone grafting for cleft alveolus in unilateral cleft lip and palate patients: a randomized prospective study. J Stomatol Oral Maxillofac Surg 2021;122:241–7.
47. Shawky H, Seifeldin SA. Does platelet-rich fibrin enhance bone quality and quantity of alveolar cleft reconstruction? Cleft Palate Craniofac J 2016;53:597–606.
48. Balaji SM. Alveolar cleft defect closure with iliac bone graft, rhBMP-2 and rhBMP-2 with zygoma shavings: comparative study. Ann Maxillofac Surg 2011;1:8–13.
49. Trujillo RL, Kadioglu O, Currier GF, Smith KS, Yetkiner E. Volumetric cleft changes in treatment with bone morphogenic protein/β-tricalcium phosphate versus grafts from the iliac crest or symphysis. J Oral Maxillofac Surg 2018;76:1991–7.
50. Thanasut A, Silkosessak O, Subbalekha K. Platelet-rich fibrin did not affect autologous bone graft in repairing alveolar clefts. J Oral Maxillofac Surg Med Pathol 2021;33:402–7.
51. Lai Y, Jiang XX, Lu M, Mao C, Cai Z, Wang C, et al. A comparative evaluation of iliac crest cortical-cancellous bone blocks graft with and without concentrated growth factors (CGFs) in secondary alveolar bone grafting: a retrospective study. J Craniofac Surg 2023;34:1789–94.
52. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 2021;12:55–61.
53. Liu M, Liu Y, Luo F. The role and mechanism of platelet-rich fibrin in alveolar bone regeneration. Biomed Pharmacother 2023;168:115795.
54. Jia K, You J, Zhu Y, Li M, Chen S, Ren S, et al. Platelet-rich fibrin as an autologous biomaterial for bone regeneration: mechanisms, applications, optimization. Front Bioeng Biotechnol 2024;12:1286035.
55. Liao Y, Fang Y, Zhu H, Huang Y, Zou G, Dai B, et al. Concentrated growth factors promote hBMSCs osteogenic differentiation in a co-culture system with HUVECs. Front Bioeng Biotechnol 2022;10:837295.
56. Xin D, Junwen Z, Jiacheng Z, Qiongyu X, Huanzong H, Peng L, et al. In vitro and in vivo study of concentrated growth factor (CGF) mediating macrophage polarization in bone defect repair. Regen Ther 2025;29:474–83.
57. Malcangi G, Inchingolo AD, Marinelli G, Casamassima L, Bassi P, Nardelli P, et al. Platelet concentrates in alveolar and periodontal bone regeneration: adjunctive benefits and clinical comparability with conventional approaches: a systematic review. J Clin Med 2026;15:3617.
58. Xu H, Liu Z. The effectiveness of using recombinant human bone morphogenetic protein-2 in the reconstruction of alveolar clefts: a meta-analysis. Front Oral Health 2026;7:1786495.
59. Von Benecke JP, Tarsitano E, Zimmermann LA, Shakesheff KM, Walsh WR, Bae HW. A narrative review on recombinant human bone morphogenetic protein 2: where are we now? Cureus 2024;16e67785.
60. Chernysheva M, Ruchko E, Eremeev A. Optimizing rhBMP-2 therapy for bone regeneration: from safety concerns to biomaterial-guided delivery systems. Int J Mol Sci 2025;26:10723.
61. Mehta S, Blagg R, Willcockson J, Gociman B, Yamashiro D, Siddiqi F. Cost-effectiveness analysis of demineralized bone matrix and rhBMP-2 versus autologous iliac crest bone grafting in alveolar cleft patients. Plast Reconstr Surg 2018;142:737–43.
62. van der Knaap-Kind LS, van der Kaaij NCW, Verkolf AE, Wolvius EB, Kragt L. A scoping review on long-term assessment methods after secondary alveolar bone grafting of patients with cleft, lip and/or palate. FACE 2025;6:355–67.
63. Khalil B, Regnstrand T, Jacobs R. A novel cone beam-CT approach for quantifying maxillary changes following secondary alveolar bone grafting in unilateral cleft patients. BMC Oral Health 2025;25:292.
64. Erkert JA, Benitez BK, Lill Y, Tapia Coron S, Mueller AA. Cone-beam computed tomography-guided volumetric assessment of secondary alveolar bone grafting. Sci Rep 2025;15:29766.
65. Saraswati I, Priaminiarti M, Nakamura N, Kiswanjaya B, Ariawan D, Suhartanto H. Volumetric measurement of alveolar clefts for bone graft planning: a systematic review. Open Dent J 2025;19e18742106389355.
66. Vicente A, Hung KF, Xu Z, Yang J, Li J, Wiedel AP, et al. Deep learning for automated alveolar cleft segmentation and bone graft volume estimation in cone-beam computed tomography imaging: a multicenter study. Oral Surg Oral Med Oral Pathol Oral Radiol 2026;141:400–8.
67. Li T, Wang YY, Liu C. The effectiveness of using platelet-rich concentrate with iliac bone graft in the repair of alveolar cleft: a meta-analysis of randomized controlled trials. Int J Oral Maxillofac Surg 2023;52:1049–56.
68. Natsir Kalla DS, Alkaabi SA, Hendra FN, Nasrun NE, Ruslin M, Forouzanfar T, et al. Stem cell-based tissue engineering for cleft defects: systematic review and meta-analysis. Cleft Palate Craniofac J 2024;61:1439–60.
69. Ryu J, Hwang DS. Descriptive analysis of autologous and xenograft materials for secondary alveolar bone grafting in cleft lip and palate patients: a literature review. Maxillofac Plast Reconstr Surg 2025;47:22.
70. Kukreja P. Outcomes of autogenous bone grafting versus alloplastic materials in maxillofacial reconstruction: systematic review. J Contemp Clin Pract 2024;10:49–56.
71. Somngam C, Samartkit S, Kanchanasurakit S, Strietzel FP, Khongkhunthian P. New bone formation of biphasic calcium phosphate bone substitute material: a systematic review and network meta-analysis of randomized controlled trials (RCTs). Int J Implant Dent 2025;11:47.
72. Lunny C, Higgins JPT, White IR, Dias S, Hutton B, Wright JM, et al. Risk of bias in network meta-analysis (RoB NMA) tool. BMJ 2025;388e079839.
73. Brignardello-Petersen R, Tomlinson G, Florez I, Rind DM, Chu D, Morgan R, et al. Grading of recommendations assessment, development, and evaluation concept article 5: addressing intransitivity in a network meta-analysis. J Clin Epidemiol 2023;160:151–9.
74. Chaimani A, Caldwell DM, Li T, Higgins JPT, Salanti G. Chapter 11: Undertaking network meta-analyses. In : Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, eds. Cochrane handbook for systematic reviews of interventions version 6.5, Cochrane; 2024.
75. Ades AE, Welton NJ, Dias S, Phillippo DM, Caldwell DM. Twenty years of network meta-analysis: continuing controversies and recent developments. Res Synth Methods 2024;15:702–27.
76. Sharifnia AM, Biros E, Cleary M. Understanding network meta-analysis: a practical introduction for nurses. J Adv Nurs 2025;81:5208–13.
77. Abu Alfaraj TM, Alruwaili BM, Alnasser RF, Alqahtani SH, Alrajhi TN, Alqahtani MA, et al. Platelet-rich fibrin as a true bone graft substitute: a systematic review and meta-analysis of its osteogenic potential in dental and maxillofacial surgery. Cureus 2025;17e89082.
78. Al Malak A, El Masri Y, Al Ziab M, Ghazi M, Salameh P. Current state of clinical trials regarding alveolar bone grafting. Cleft Palate Craniofac J 2025;62:558–67.

Article information Continued

Fig. 1.

Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 flow diagram of study identification, screening, and inclusion. Six databases yielded 1,228 records, of which 21 studies (23 reports) met the eligibility criteria. Sixteen studies were eligible for quantitative synthesis, and five were reserved for prespecified sensitivity analyses.

Fig. 2.

Risk-of-bias assessment generated using robvis. (A, B) RoB 2 traffic-light plot and weighted summary bar plot for the 14 randomized trials. (C, D) ROBINS-I traffic-light plot and weighted summary bar plot for the seven nonrandomized studies. The CHLA row represents the pooled Francis (2013) [32], Liang (2017) [31], and Hammoudeh (2017) [30] cohort, assessed using the index report. Green indicates low risk; yellow, some concerns (RoB 2) or moderate risk (ROBINS-I); and red, high risk (RoB 2) or serious risk (ROBINS-I). RoB 2, Cochrane risk-of-bias tool for randomized trials, version 2; ROBINS-I, Risk Of Bias In Non-randomized Studies of Interventions; CHLA, Children’s Hospital Los Angeles.

Fig. 3.

Network geometry by outcome. Nodes represent treatments, and edges represent direct comparisons. Node size reflects the number of patients or, for graft success, the contributing study’s analysis unit (patients, cleft sides, or graft exposures; see Results); edge labels indicate the number of studies. (A) New bone formation; (B) bone density; (C) graft volume; (D) graft success. Autogenous bone graft is the common reference. PRP, platelet-rich plasma; rhBMP-2, recombinant human bone morphogenetic protein-2; PRF, platelet-rich fibrin; BMAC, bone marrow aspirate concentrate; TE, tissue-engineered construct; CGF, concentrated growth factor.

Fig. 4.

Forest plots of network meta-analysis estimates for each treatment versus autogenous bone graft, ordered by P-score. (A) New bone formation (SMD); (B) bone density (SMD); (C) graft volume (SMD); (D) graft success (RR). Squares indicate point estimates, and horizontal lines indicate 95% CIs. SMD, standardized mean difference; RR, risk ratio; CI, confidence interval; rhBMP-2, recombinant human bone morphogenetic protein-2; PRF, platelet-rich fibrin; PRP, platelet-rich plasma; BMAC, bone marrow aspirate concentrate; TE, tissue-engineered construct; CGF, concentrated growth factor.

Fig. 5.

Comparison-adjusted funnel plots by outcome. (A) New bone formation; (B) bone density; (C) graft volume; (D) graft success. These plots are exploratory because every comparison included fewer than 10 studies; a formal Egger test is reported only for the primary outcome (p=0.68). PRF, platelet-rich fibrin; PRP, platelet-rich plasma; rhBMP-2, recombinant human bone morphogenetic protein-2; BMAC, bone marrow aspirate concentrate; TE, tissue-engineered construct; CGF, concentrated growth factor.

Fig. 6.

Heatmap of treatment rankings (P-scores) across four outcomes. Higher P-scores, shown in green, indicate higher rank; color represents rank, not statistical significance. Asterisks identify treatments significantly superior to autogenous bone graft, the common reference. PRF, platelet-rich fibrin; NR, treatment not connected in that outcome network; CGF, concentrated growth factor; PRP, platelet-rich plasma; BMAC, bone marrow aspirate concentrate; TE, tissue-engineered; MSC, mesenchymal stem cell; rhBMP-2, recombinant human bone morphogenetic protein-2.

Fig. 7.

Biological mechanisms of regenerative agents in secondary alveolar cleft grafting. Autogenous bone provides the osteogenic, osteoinductive, and osteoconductive reference standard. rhBMP-2 drives osteoblast differentiation through Smad signaling; platelet concentrates (PRF, CGF, and PRP) release bone-healing growth factors; and BMAC supplies osteogenic cells. These pathways converge on osteoblast activity, angiogenesis, new bone formation, and graft consolidation. rhBMP-2, recombinant human bone morphogenetic protein-2; PRF, platelet-rich fibrin; CGF, concentrated growth factor; PRP, platelet-rich plasma; BMAC, bone marrow aspirate concentrate; DBM, demineralized bone matrix; βTCP, beta-tricalcium phosphate; HA/TCP, hydroxyapatite/tricalcium phosphate; BMP, bone morphogenetic protein; FDA, Food and Drug Administration; PDGF, platelet-derived growth factor; TGF-β, transforming growth factor beta; VEGF, vascular endothelial growth factor; BM-MSC, bone marrow-derived mesenchymal stem cell.

Table 1.

Eligibility criteria by population, intervention, comparison, outcomes, and study design

Parameter Criteria
Population Patients of any age undergoing secondary or late secondary alveolar bone grafting for cleft lip and/or palate involving the alveolus.
Intervention A regenerative agent used alone or with autogenous bone: recombinant human bone morphogenetic protein-2, platelet-rich plasma, platelet-rich fibrin (including advanced and injectable variants), concentrated growth factor, bone marrow aspirate concentrate, adipose-derived stromal vascular fraction, and mesenchymal stem cell or tissue-engineered constructs.
Comparison Autogenous bone graft alone, usually from the anterior iliac crest, served as the common reference; regenerative agents were also compared with one another across the network.
Outcomes Four mutually exclusive constructs were defined a priori. The primary outcome was new bone formation, expressed as percentage bone fill or bone formation ratio on cone-beam computed tomography or computed tomography. Secondary outcomes were graft volume (absolute volume in mm³ or cm³), bone density (Hounsfield units or equivalent radiographic density), and graft success (Bergland or Chelsea scale, or an equivalent clinical definition). When a study reported multiple eligible metrics, one metric was assigned to one network according to a prespecified hierarchy; the four networks were analyzed separately without pooling across outcomes. Analyses used absolute values at the follow-up closest to 6 months. Postoperative complications (infection and graft failure) and donor-site morbidity were summarized narratively.
Study design Included: randomized controlled trials and prospective or retrospective controlled comparative studies reporting at least one eligible outcome for two or more groups. Excluded: case reports, single-arm series without a comparator, animal and in vitro studies, and narrative reviews.

Table 2.

Certainty of evidence for each network estimate

Outcome Comparison Effect estimate (95% CI) Studies/patients Certainty Reasons for downgrading
New bone formation (SMD) PRF vs. autograft 1.21 (–0.44 to 2.87) 2/39 ⊕⊖⊖⊖ Risk of bias, imprecision, heterogeneity
New bone formation (SMD) PRP vs. autograft 0.30 (–1.87 to 2.48) 1/40 ⊕⊖⊖⊖ Imprecision, heterogeneity
New bone formation (SMD) rhBMP-2 vs. autograft 0.08 (–1.48 to 1.63) 2/45 ⊕⊖⊖⊖ Risk of bias, indirectness, imprecision, heterogeneity
New bone formation (SMD) rhBMP-2+zygoma vs. autograft 1.77 (–0.36 to 3.90) 1/9 ⊕⊖⊖⊖ Risk of bias, indirectness, imprecision, heterogeneity
Bone density (SMD) PRF vs. autograft 3.15 (–3.56 to 9.86) 2/37 ⊕⊖⊖⊖ Indirectness, imprecision, heterogeneity
Bone density (SMD) PRP vs. autograft 3.15 1/25 ⊕⊖⊖⊖ Imprecision, heterogeneity
Bone density (SMD) BMAC vs. autograft 3.03 1/18 ⊕⊕⊖⊖ Imprecision, heterogeneity
Bone density (SMD) Tissue-engineered construct vs. autograft –0.61 1/5 ⊕⊖⊖⊖ Imprecision, heterogeneity
Graft volume (SMD) BMAC vs. autograft 2.36 (1.51 to 3.21) 1/18 ⊕⊕⊖⊖ Indirectness, imprecision
Graft volume (SMD) PRP vs. autograft 0.52 (–0.11 to 1.15) 1/20 ⊕⊕⊖⊖ Imprecision
Graft volume (SMD) Tissue-engineered construct vs. autograft 0.12 (–1.12 to 1.37) 1/5 ⊕⊖⊖⊖ Imprecision
Graft success (RR) PRF vs. autograft 1.46 (1.07 to 2.01) 2/40 ⊕⊕⊕⊖ Risk of bias
Graft success (RR) CGF vs. autograft 1.21 (1.02 to 1.43) 1/43 ⊕⊕⊖⊖ Risk of bias, indirectness, imprecision
Graft success (RR) PRP vs. autograft 1.30 (0.77 to 2.21) 1/25 ⊕⊖⊖⊖ Imprecision
Graft success (RR) rhBMP-2 vs. autograft 1.02 (0.96 to 1.08) 2/259 ⊕⊕⊖⊖ Risk of bias, indirectness
Graft success (RR) PRF vs. rhBMP-2 1.44 (1.04 to 1.99) Indirect only ⊕⊕⊖⊖ Risk of bias, indirectness, imprecision

CI, confidence interval; SMD, standardized mean difference; PRF, platelet-rich fibrin; PRP, platelet-rich plasma; rhBMP-2, recombinant human bone morphogenetic protein-2; BMAC, bone marrow aspirate concentrate; RR, risk ratio; CGF, concentrated growth factor.

Table 3.

Characteristics of the 16 studies eligible for quantitative synthesis

Study (year, country, design) Cleft type N (intervention/comparator) Age (yr)a) Intervention agent (carrier) Comparator Outcome network
Lee (2021, USA, retrospective cohort) [43] CL/P with alveolar cleft (unilateral+bilateral) rhBMP-2 35/AICBG 80 (130 clefts; 95 analyzed) 12.1 ± 6.1 rhBMP-2 (collagen sponge ± allogeneic bone) AICBG (anterior iliac crest) Graft success
Yadav (2026, India, RCT 1:1:1) [24] Alveolar cleft (unilateral+bilateral) PRP 25/PRF 25/ABG 25 13.1/13.0/12.8 PRP; PRF (no carrier) ABG alone (anterior iliac crest) Bone density; graft success
Kadry (2021, Egypt, RCT) [44] Unilateral alveolar cleft Tissue-engineered construct 5/AIC 5 10 (9–11) Tissue-engineered construct: collagen+BM-MSCs (collagen scaffold) AIC autogenous particulate bone Bone density; graft volume
Shabaan (2023, Egypt, RCT) [45] Unilateral alveolar cleft BMAC+iliac 18/iliac 18 9 (8–11) BMAC+iliac (collagen membrane cover) Iliac cancellous bone alone Bone density; graft volume
Dayashankara Rao (2021, India, RCT) [46] Unilateral complete cleft alveolus Injectable and advanced PRF+iliac 15/iliac 15 9.7/8.5 Injectable+advanced PRF (PRF membrane) Iliac bone graft alone Graft success
Desai (2024, India, RCT) [41] Unilateral cleft alveolus BMAC+PRF+iliac 15/BMAC+iliac 15 13 PRF (+BMAC; no carrier) Iliac+BMAC (no PRF) None
Eid (2024, Egypt, RCT 3 groups) [39] Alveolar cleft (unilateral+bilateral) PRF+chin 12/chin alone 12 8.55 (7–12) PRF+chin bone (interpositional membrane) Autogenous chin (symphysis) bone alone Bone density
Shawky (2016, Egypt, RCT) [47] Unilateral alveolar cleft PRF+iliac 12/iliac 12 9–14 PRF (no carrier) Anterior iliac crest bone alone New bone formation
Balaji (2011, India, retrospective comparative) [48] Nonsyndromic alveolar cleft (unilateral+bilateral) rhBMP-2 13/rhBMP-2+zygoma 9/iliac 20 ~7 rhBMP-2; rhBMP-2+zygomatic shavings (absorbable collagen sheet) Iliac crest graft New bone formation
Trujillo (2018, USA, retrospective cohort) [49] Alveolar cleft (unilateral+bilateral) rhBMP-2/βTCP 12/iliac 9/symphysis 11 (clefts) ~10.5 rhBMP-2 in βTCP scaffold (βTCP+collagen sponge) Iliac crest; mandibular symphysis New bone formation
Kurimori (2026, Brazil, RCT prospective) [42] Unilateral alveolar cleft (permanent dentition) SVF+iliac 7/iliac 8 (15 analyzed) 27.6/17.35 SVF, adipose-derived (no carrier) Iliac crest bone alone None
Thanasut (2021, Thailand, RCT prospective) [50] Alveolar cleft (unilateral+bilateral) PRF+PCBM 8 sites/PCBM 7 sites (13 patients) 9.8/10.3 PRF, liquid+membrane (PRF membrane) Iliac PCBM alone New bone formation
Lai (2023, China, retrospective comparative) [51] Unilateral alveolar cleft CGF+bone block 43/bone block 43 (17 vs. 17 imaged) 11.1/10.3 CGF (autogenous bone block) Iliac cortical-cancellous bone block alone Graft success
Chen (2020, China, RCT prospective) [38] Unilateral alveolar cleft PRP+iliac 20/iliac 20 8–13 PRP (no carrier) Iliac cancellous bone alone New bone formation; graft volume
Kahan (2026, USA, retrospective cohort) [40] Unilateral alveolar cleft HA/TCP+rhBMP-2 16/ICBG+rhBMP-2 65/ICBG 37 (105 imaged) 9/8/8 (IQR 7–10, all arms) rhBMP-2 on an HA/TCP scaffold and as an ICBG adjunct (HA/TCP 15/85+collagen sponge) ICBG (autogenous iliac) alone None
CHLA cluster (2013–2017, USA, retrospective cohort) [30-32] CL/P with alveolar cleft (unilateral+bilateral) rhBMP-2/DBM 198/ICBG 216 (501 procedures) 11.7/11.3 rhBMP-2+DBM (DBM+collagen sponge) ICBG (autogenous iliac) Graft success

CL/P, cleft lip and/or palate; rhBMP-2, recombinant human bone morphogenetic protein-2; AICBG, anterior iliac crest bone graft; RCT, randomized controlled trial; PRP, platelet-rich plasma; PRF, platelet-rich fibrin; ABG, autogenous bone graft; AIC, anterior iliac crest; BM-MSCs, bone marrow-derived mesenchymal stem cells; BMAC, bone marrow aspirate concentrate; βTCP, beta-tricalcium phosphate; SVF, stromal vascular fraction; PCBM, particulate cancellous bone and marrow; CGF, concentrated growth factor; IQR, interquartile range; HA, hydroxyapatite; TCP, tricalcium phosphate; ICBG, iliac crest bone graft; CHLA, Children’s Hospital Los Angeles; DBM, demineralized bone matrix; SD, standard deviation.

a)

Age is reported as mean±SD [43]; mean (range) [39]; median (range) [44,45]; range [38,47]; an approximate mean as reported in the source [48,49]; or values per study arm separated by a slash where no single pooled value was reported [24,30–32,40,42,46,50,51]; or a single value without further specification of the statistic type in the source article [41].

Table 4.

Studies reserved for sensitivity analyses

Study (year) Country Design Intervention vs. comparator Reason reserved for sensitivity analysis
Bajestan (2017) [33] USA RCT Cell-based graft (stem/stromal cells) vs. autogenous block graft Mixed population with trauma or cleft; primary outcome was horizontal ridge width for implant placement, not new bone formation
Aldaghir (2024) [34] Iraq RCT (coin-toss randomization) Maxillary cortical bone chips+PRF vs. iliac cancellous bone Both arms used autogenous bone; the comparison combines differences in bone source and agent rather than agent versus autograft
Bedeer (2024) [35] Egypt RCT (noninferiority) Bovine xenograft+PRF vs. iliac bone Intervention combines a bone substitute with the agent; retained for the substitute-plus-concentrate subgroup analysis
Alnajjar (2020) [36] Syria RCT Bovine xenograft+injectable PRF vs. iliac bone Same reason as Bedeer (2024) [35]
Seif (2026) [37] Egypt/Saudi Arabia Retrospective comparative A-PRF+allograft (DFDB) vs. anterior iliac crest Intervention combines an allograft substitute with the agent; retained for the substitute-plus-concentrate subgroup analysis

RCT, randomized controlled trial; PRF, platelet-rich fibrin; A-PRF, advanced platelet-rich fibrin; DFDB, demineralized freeze-dried bone.

Table 5.

Outcome data and the metric entered into each network

Study (year) Reported outcome data (mean ± SD) Imaging tool Metric analyzed Time point analyzed
Lee (2021) [43] Fill and volume not reported; vertical bone height assessed by Bergland scale. Success: 90.3% vs. 89.1% (p = 0.85) Panoramic/periapical Graft success: Bergland type 1–2 (vertical bone height) ≥ 6 mo (mean 22.3)
Yadav (2026) [24] Density 6 mo (coronal/middle/apical): PRF 465.8 ± 18.3/440.7 ± 19.2/425.2 ± 17.9; PRP 410.6 ± 22.1/375.3 ± 20.0/360.5 ± 19.4; ABG 345.2 ± 20.4/310.4 ± 18.9/298.1 ± 21.3. IOPA, occlusal, OPG Bone density: mean across the three thirds. Graft success: Bergland type I 6 mo
Bergland type I: PRF 12, PRP 8, ABG 6 (of 25)
Kadry (2021) [44] Volume: 6 mo 1,096.17 ± 661.63 vs. 1,010.6 ± 708.05 mm³ (p = 0.91); 12 mo also reported. CT Graft volume: newly formed bone volume (6-mo minus immediate postoperative value). Bone density: HU 6 mo (of 6 and 12)
Density: 6 mo 312.84 ± 116.21 HU vs. 408.90 ± 190.50 HU (p = 0.364)
Shabaan (2023) [45] Volume: 6 mo 709 ± 90 vs. 517 ± 72; 12 mo 681 ± 86 vs. 477 ± 65. CBCT Graft volume: BV6, residual graft volume measured by freehand tracing. 6 mo (of 6 and 12)
Density: 6 mo 744 ± 93 vs. 502 ± 64; 12 mo 741 ± 80 vs. 510 ± 64. Bone density: BD6 (HU)
All p < 0.001
Dayashankara Rao (2021) [46] Fill and volume not reported. Bergland success (type 1–2): 3 mo, 100% vs. 100%; 6 mo, 93.3% vs. 60% IOPA Graft success: Bergland type 1–2, defined as 0%–50% resorption 6 mo (of 3 and 6)
Desai (2024) [41] Graft volume 12 mo 2.28 vs. 1.95 cm³; regenerated bone 75% vs. 70%; resorption 25% vs. 30% CT Not analyzed: both arms contained BMAC, with no autograft-alone comparator -
Eid (2024) [39] Density: 3 mo 910.20 ± 123.03 vs. 870.3 ± 84.99; 9 mo 752.95 ± 102.64 vs. 771.3 ± 43.55 (p = 0.003) CT Bone density: mineral density on axial CT 9 mo (of 3 and 9)
Shawky (2016) [47] % new bone: 82.6% ± 3.9% vs. 68.38% ± 6.67% (p < 0.05). CT New bone formation: (preoperative defect − residual defect)/preoperative defect × 100 6 mo
Density NS (360.82 HU vs. 384.03 HU), reported without SD
Balaji (2011) [48] Bone deposition efficiency: rhBMP-2 89.42% ± 2.22%; rhBMP-2+zygoma 95.38% ± 1.61%; iliac 87.90% ± 5.17% (p < 0.001) OPG (planimetry) New bone formation: (preoperative − 4-mo radiolucent area)/preoperative × 100 4 mo
Trujillo (2018) [49] % new bone: rhBMP-2/βTCP 81.2% ± 5.8%; iliac 85.5% ± 6.6%; symphysis 80.6% ± 7.4% (p = 0.854) CBCT New bone formation: (preoperative defect − residual defect)/preoperative defect × 100; iliac and symphysis groups pooled as autograft ≥ 6 mo; imaging interval 13.3–22.4 mo by arm
Kurimori (2026) [42] New bone 6 mo 0.69 cm³ vs. 0.44 cm³ (p = 0.302); cleft density 336.55 HU vs. 297.11 HU (p = 0.685) CT (3D) Not analyzed: outcomes could not be expressed on a common scale with the other trials -
Thanasut (2021) [50] Regenerated bone volume 6 mo: 64.9% ± 19.6% vs. 67.0% ± 8.7% (p = 0.817); relative density 0.74 ± 0.10 vs. 0.76 ± 0.08 CBCT New bone formation: percentage regenerated bone volume on CBCT. 6 mo
Analysis unit: sites, not patients
Lai (2023) [51] Reported as resorption, not fill: 12 mo 35.66% ± 15.80% vs. 41.39% ± 19.57% (p = 0.355). CBCT Graft success: clinical absence of sequestrum and oronasal fistula in all 86 patients 12 mo
Graft success 95.3% vs. 79.1% (p = 0.025)
Chen (2020) [38] Bone formation ratio: 46.97% ± 18.49% vs. 42.54% ± 9.31% (p = 0.71); formed volume 550.35 ± 283.42 mm³ vs. 435.13 ± 134.02 mm³ (p = 0.26) CT (CAE) New bone formation: BF% = FV/AV × 100. Graft volume: formed bone volume. 6 mo
Both were derived from the same measurement
Kahan (2026) [40] % graft take (median, IQR): 68.0% (45.9–93.1); 44.2% (24.5–63.1); 25.1% (5.2–43.5) CBCT Not analyzed: success defined as the clinical need for regrafting; volumetric outcome reported as medians with IQRs -
CHLA cluster (2013–2017) [30-32] Clinical success 90% vs. 88.4% (NS). % bone fill 31.6% vs. 32.5%, density identical 1.38 g/cm³ Occlusal 2D+CBCT Graft success: clinical, with no reoperation required (205/228 vs. 214/242, index report) Mean 2.9–4.1 yr

SD, standard deviation; PRF, platelet-rich fibrin; PRP, platelet-rich plasma; ABG, autogenous bone graft; IOPA, intraoral periapical radiography; OPG, orthopantomography; HU, Hounsfield unit; CT, computed tomography; CBCT, cone-beam computed tomography; BV6, bone volume at 6 months; BD6, bone density at 6 months; BMAC, bone marrow aspirate concentrate; NS, not significant; rhBMP-2, recombinant human bone morphogenetic protein-2; βTCP, beta-tricalcium phosphate; 3D, three-dimensional; CAE, computeraided engineering; BF%, bone formation ratio; FV, formed bone volume; AV, alveolar cleft volume; IQR, interquartile range; CHLA, Children’s Hospital Los Angeles; 2D, two-dimensional.